Good MorningEquities shrugged off another hot month of inflation data last week in favor of earnings. The S&P 500 moved up to set a new all-time high on Friday, the question now is whether or not the index can keep it. Along with inflation, the Delta covid variant has emerged as a real threat to the market and could have a serious impact on the second half of the year. Estimates for earnings continue to rise but the pace has slowed over the past week as a rising number of companies warn the market about the second-half outlook.
This week, the focus will be on the consumer. Not only are we expecting a read on retail sales but earnings reports from a host of major retailers including Home Depot and Walmart are due as well. The big-box retailers are expected to post slight YOY revenue declines in the face of last year's tough comparisons.
Featured: Elon's new "super startup" (Ad) 
|
Markets | |
Inovio (NYSE: INO) stock is trying to hang on to a small gain after the company reported earnings on August 9. Shares of the biotech company are essentially flat for the year, and yet INO stockholders have been taken on a wild ride for much longer than that. There are a couple of reasons for that.... Read the Full Story |
|
From Our Partners | | If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answer to a multi-variable problem. Withdrawal sequencing, sequence-of-returns risk, Roth conversion timing, and legacy goals can all shift your real number significantly.
Research from Vanguard suggests advisor best practices - covering allocation, rebalancing, tax management, and behavioral coaching - may add roughly 3% in net annual return potential. Morningstar's 2025 data shows the average investor return gap is 1.2% per year due to mistimed buying and selling.
Get matched with a fiduciary advisor in your area at no cost and with no obligation to hire. | | Answer three quick questions to find your advisor match today |
|
Consumer Discretionary | | With the way that the sports betting market continues to grow in the United States, there are going to be plenty of opportunities for companies to establish themselves as leaders in this burgeoning industry in the coming years. Bettors are quickly becoming more accustomed to handling their business ... Read the Full Story |
|
Business Services | |
High-Flying Cricut, Inc Returns To Earth
Cricut, Inc (NASDAQ: CRCT) caught our attention earlier this year shortly after its IPO. The company's Q1 earnings report was a blowout and opened our eyes to what we see as the new age for crafting. Cricut, Inc provides a range of Internet-connected craft... Read the Full Story |
|
From Our Partners | | CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highlander Silver before 741%, and Orogen Royalty before 416%. He also publicly predicted Newmont's 126% gain in 2025.
Now Goggin says the 1974 petrodollar agreement between Washington and Riyadh has quietly expired, central banks are buying gold at the fastest pace since 1950, and a major monetary shift is underway. He has identified four specific positions - plus two bonus opportunities for readers. | | Read the full briefing and see all four positions plus two bonuses |
|
Consumer Discretionary | | Shares of Disney (NYSE: DIS) look set to end the week on a high as the street digests their Q3 earnings report which was released after Thursday’s session ended. Both the top line and bottom line numbers comfortably beat analyst expectations, with GAAP EPS 60% higher than the consensus and rev... Read the Full Story |
|
Finance | | It’s a bit surprising that capital markets stocks don’t attract more attention from investors and traders, especially given that these companies offer exchange marketplaces where financial securities can be bought and sold. Along with providing a way for traders to buy and sell things li... Read the Full Story |
|
From Our Partners | | Nvidia is up 203% this year. Microsoft, Amazon, Apple, and Alphabet have each surged between 36% and 62%. But one analyst believes the biggest AI winner hasn't been discovered yet.
He calls it the 'AI Wonder Stock' - a company with a market cap less than 1/1,000th of Microsoft's, still early-stage while the AI wave builds momentum. | | Watch the free presentation to see the AI Wonder Stock now |
|
Finance | | Brookfield Asset Management (NYSE: BAM) rallied to a new high Wednesday before retreating in Thursday’s session following the company’s second-quarter earnings report.
The stock closed at $56.55 Thursday, down $0.83, or 1.45%. It skidded 4.22% in the first hour of trade, before rallyi... Read the Full Story |
|
Technology | | Digital engagement company Bridgeline Digital (NASDAQ: BLIN) experienced a flood of buying followed by a cascade of selling as a meme stock momentum mover. The Company normally trades under 100,000 shares a day when it was trading in the $2s but experienced a powerful surge in both volume and price ... Read the Full Story |
|
Markets | |
What happens when your employer doesn't offer you a 401(k)? You lose out on money, naturally. Intuitively, you know that. But have you ever stopped to calculate just how much you're losing out on if you don't have an employer plan?
Employer-sponsored 401(k) plans have turned into one of the most ... Read the Full Story |
|
Technology | |
Shares of The Trade Desk (NASDAQ: TTD) have been on a roller coaster after a stellar earnings report. However, TTD stock continues to establish higher levels of support. And the stock is within range of its 52-week high set at the end of December.
If analyst sentiment is any indication, that sh... Read the Full Story |
|
Markets | | Electrical wiring manufacturer Emcore Wire Corporation (NASDAQ: WIRE) stock surged on its absolute blowout Q2 2021 earnings causing shares to violently reverse the downtrend and surge back up to all-time highs. The massive earnings blowout was largely due to rise in copper prices in addition to the ... Read the Full Story |
|
The Early Bird Stock Of The Day Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. | | View Today's Stock Pick |
|
